Results 31 to 40 of about 169,585 (295)

Perspectives on Precision Psychiatry Using Antipsychotics in the Management of Bipolar Disorder

Brain Sciences
Background/Objectives: Precision medicine is not just hype. Instead, it represents a high bar for developing more effective, safer, and better-tolerated therapies in medicine, without exception in psychiatry, including bipolar disorder (BD). A burgeoning
Michele Fornaro, Alessandro Miola, Domenico De Berardis, Alessio Squassina, Mirko Manchia, Marco Solmi   +5 more
doaj   +1 more source

Pulmonary embolism in a patient with neuroleptic malignant syndrome

Hematology Reports, 2018
Venous thromboembolism is one of the complications in patients prescribed antipsychotic medications. Neuroleptic malignant syndrome (NMS) is a rare side effect of antipsychotic medications in this population.
Mosaad Almegren
doaj   +1 more source

Antipsychotic-Related Risks of Type 2 Diabetes Mellitus in Enrollees With Schizophrenia in the National Basic Public Health Service Program in Hunan Province, China

Frontiers in Psychiatry, 2022
BackgroundAntipsychotics contribute to the development of type 2 diabetes mellitus (T2DM) in individuals with schizophrenia. However, the extent of the relationship between antipsychotic use and T2DM varies in different settings, and the magnitude of the
Feiyun Ouyang, Jun He, Xunjie Cheng, Wei Zhou, Shuiyuan Xiao, Junqun Fang   +5 more
doaj   +1 more source

Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study

Neuropsychiatric Disease and Treatment, 2021
Masaomi Iyo,1 Jun Ishigooka,2 Masatoshi Nakamura,3 Reiko Sakaguchi,4 Keisuke Okamoto,5 Yongcai Mao,6 Joyce Tsai,7 Alison Fitzgerald,8 Kentaro Takai,9 Teruhiko Higuchi10,11 1Department of Psychiatry, Graduate School of Medicine, Chiba University, Chiba ...
Iyo M, Ishigooka J, Nakamura M, Sakaguchi R, Okamoto K, Mao Y, Tsai J, Fitzgerald A, Takai K, Higuchi T   +9 more
doaj  

Evidence and Extrapolation: Mechanisms for Regulating Off-Label Uses of Drugs and Devices [PDF]

, 2014
A recurring, foundational issue for evidence-based regulation is deciding whether to extend governmental approval from an existing use with sufficient current evidence of safety and efficacy to a novel use for which such evidence is currently lacking ...
Abbott, Ryan, Ayres, Ian
core   +3 more sources

Effect of Metformin on Antipsychotic-Induced Metabolic Dysfunction: The Potential Role of Gut-Brain Axis

Frontiers in Pharmacology, 2019
Antipsychotics are the first-line medications prescribed for patients with schizophrenia or other mental disorders. Cumulative evidence has revealed that metabolic dysfunctions frequently occur in patients receiving antipsychotics, especially second ...
Chao Luo, Chao Luo, Chao Luo, Xu Wang, Xu Wang, Hanxue Huang, Hanxue Huang, Xiaoyuan Mao, Xiaoyuan Mao, Honghao Zhou, Honghao Zhou, Honghao Zhou, Zhaoqian Liu, Zhaoqian Liu, Zhaoqian Liu   +14 more
doaj   +1 more source

The impact of pimavanserin on psychotic phenotypes and tau phosphorylation in the P301L/COMT– and rTg(P301L)4510 mouse models of Alzheimer's disease

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022
Introduction Psychosis in Alzheimer's disease (AD) is associated with grave clinical consequences including a precipitous cognitive decline and a hastened demise.
Heidy Jimenez, Leslie Adrien, Adam Wolin, John Eun, Eric H. Chang, Ethan S. Burstein, Jesus Gomar, Peter Davies, Jeremy Koppel   +8 more
doaj   +1 more source

Cutaneous Phosphorylated Alpha‐Synuclein in Lewy Body Dementia

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine the test performance of cutaneous phosphorylated alpha‐synuclein (P‐SYN) in dementia with Lewy bodies (DLB), individuals with reduced Montreal Cognitive Assessment (MoCA) and healthy controls. Methods This is the first subgroup analysis of the Synuclein‐One study, a prospective, blinded study evaluating P‐SYN detection ...
Christopher H. Gibbons, Todd Levine, Charles H. Adler, Bailey Bellaire, Ningshan Wang, Pinky Agarwal, Georgina M. Aldridge, Alexandru Barboi, Daniel Claassen, Virgilio G. H. Evidente, Douglas Galasko, Alejandra Gonzalez‐Duarte, Ramon Gil, Mark Gudesblatt, Stuart H. Isaacson, Horacio Kaufmann, Pravin Khemani, Rajeev Kumar, Guillaume Lamotte, Andy J. Liu, Nikolaus R. McFarland, Mitchell G. Miglis, Adam Reynolds, Gregory A. Sahagian, Marie‐Helene Saint‐Hilaire, Julie B. Schwartzbard, Wolfgang Singer, Michael J. Soileau, Steven Vernino, Patricio Millar Vernetti, Oleg Yerstein, Roy Freeman   +31 more
wiley   +1 more source

Prescriber Attitudes, Experiences, and Proclivities Toward Digital Medicine and How They Influence Adoption of Digital Medicine Platforms

Neuropsychiatric Disease and Treatment, 2021
Charles Ruetsch,1 Tigwa Davis,1 Joshua N Liberman,1 Dawn I Velligan,2 Delbert Robinson,3 Chris Jaeger,4 William Carpenter,5 Felica Forma6 1Health Analytics, LLC, Columbia, MD, USA; 2Department of Psychiatry, University of Texas Health Science Center at ...
Ruetsch C, Davis T, Liberman JN, Velligan DI, Robinson D, Jaeger C, Carpenter W, Forma F   +7 more
doaj  

Negative Allosteric Modulators of mGlu7 Receptor as Putative Antipsychotic Drugs

Frontiers in Molecular Neuroscience, 2018
The data concerning antipsychotic-like activity of negative allosteric modulators (NAMs)/antagonists of mGlu7 receptors are limited. The only available ligands for this receptor are MMPIP and ADX71743.
Paulina Cieślik, Monika Woźniak, Katarzyna Kaczorowska, Piotr Brański, Grzegorz Burnat, Agnieszka Chocyk, Bartosz Bobula, Piotr Gruca, Ewa Litwa, Agnieszka Pałucha-Poniewiera, Agnieszka Wąsik, Andrzej Pilc, Joanna Wierońska   +12 more
doaj   +1 more source